Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon Alfa-2b in Pre-fibrotic/Early or Overt Primary Myelofibrosis (HOPE-PMF)
NCT06468033Phase 3Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in primary myelofibrosis (PMF) comparing Ropeginterferon alfa-2b (P1101) with Placebo control (2 arms). Primary endpoints: Number of Participants with Platelet count equal or less (<=) 400 x 10^9/L at 80 weeks, Number of Participants with White Blood Cells (WBC) count equal or less (<=) 10 x 10^9/L at 80 weeks and 4 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
primary myelofibrosis (PMF)
Beyond the preview
Go deeper on NCT06468033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468033.